Cure My Disease

Don't miss your cure!

 Log in / Sign up

New imaging algorithm could spot hidden cause of chest pain without invasive procedures

NCT ID NCT05634031

Diagnosis Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study aims to create a non-invasive diagnostic algorithm using PET imaging and CT scans to identify microvascular angina in patients who have chest pain and signs of ischemia but no blocked coronary arteries. About 70 participants with symptoms of angina or shortness of breath and non-obstructive coronary artery disease will undergo imaging tests. A small subset may also have an invasive coronary reactivity test for comparison. The goal is to improve diagnosis and management of this often-missed condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PET imaging, coronary CT angiogram, and functional angiography (coronary reactivity test)
What this could lead to
If successful, this could provide a non-invasive way to diagnose microvascular angina, reducing the need for invasive procedures and improving patient care.
What could go wrong
This is a small, early-stage study focused on developing a diagnostic algorithm, not a treatment. The algorithm may not prove accurate enough for widespread use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2023

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Patients with symptoms of exertional angina and/or dyspnea (confirmed on Seattle Angina Questionnaire and Rose Dyspnea Questionnaire) * Evidence of non-obstructive CAD on CCTA or coronary angiography (no stenosis \>50% and/or FFR if performed \>0.80) Exclusion criteria: * Patients with reduced LVEF (\<50%) or diagnosis of cardiomyopathy * Patients with co-existent moderate or severe valve disease * Patients with eGFR \<30 ml/min/m2 * History of prior coronary revascularization * Non-coronary indication for CCTA or coronary angiogram determining eligibility * Contraindications to regadenoson (severe asthma/chronic obstructive pulmonary disease, brady-arrhythmias, or systolic blood pressure \<90 mm Hg) * Inability to provide informed consent * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Angina are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Angina Pectoris intermediate coronary syndrome nonobstructive coronary artery disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Angina Non-obstructive coronary artery disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Mount Sinai Morningside

    RECRUITING

    New York, New York, 10025, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.